JP Morgan Chase’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-459,229
| Closed | -$8.93M | – | 5862 |
|
|
2018
Q1 | $8.93M | Buy |
459,229
+81,430
| +22% | +$1.6M | ﹤0.01% | 2107 |
|
|
2017
Q4 | $6.29M | Buy |
377,799
+71,937
| +24% | +$1.32M | ﹤0.01% | 2486 |
|
|
2017
Q3 | $6.46M | Sell |
305,862
-88,875
| -23% | -$1.7M | ﹤0.01% | 2363 |
|
|
2017
Q2 | $6.36M | Sell |
394,737
-130,496
| -25% | -$1.93M | ﹤0.01% | 2312 |
|
|
2017
Q1 | $6.64M | Buy |
525,233
+49,252
| +10% | +$595K | ﹤0.01% | 2232 |
|
|
2016
Q4 | $6.31M | Buy |
475,981
+384,106
| +418% | +$6.57M | ﹤0.01% | 2269 |
|
|
2016
Q3 | $2.18M | Buy |
91,875
+5,670
| +7% | +$152K | ﹤0.01% | 2748 |
|
|
2016
Q2 | $2.48M | Buy |
86,205
+14,008
| +19% | +$457K | ﹤0.01% | 2697 |
|
|
2016
Q1 | $2.31M | Sell |
72,197
-19,399
| -21% | -$682K | ﹤0.01% | 2626 |
|
|
2015
Q4 | $3.92M | Sell |
91,596
-7,839
| -8% | -$313K | ﹤0.01% | 2370 |
|
|
2015
Q3 | $3.5M | Buy |
99,435
+2,016
| +2% | +$90.8K | ﹤0.01% | 2452 |
|
|
2015
Q2 | $4.47M | Sell |
97,419
-22,707
| -19% | -$1.08M | ﹤0.01% | 2457 |
|
|
2015
Q1 | $5.63M | Sell |
120,126
-208,900
| -63% | -$8.31M | ﹤0.01% | 2265 |
|
|
2014
Q4 | $10.4M | Sell |
329,026
-102,577
| -24% | -$3M | ﹤0.01% | 1922 |
|
|
2014
Q3 | $10.2M | Sell |
431,603
-85,698
| -17% | -$2.2M | ﹤0.01% | 1908 |
|
|
2014
Q2 | $15.5M | Buy |
517,301
+287,170
| +125% | +$7.75M | ﹤0.01% | 1493 |
|
|
2014
Q1 | $6.08M | Sell |
230,131
-350,326
| -60% | -$8.76M | ﹤0.01% | 1973 |
|
|
2013
Q4 | $14.6M | Buy |
580,457
+23,634
| +4% | +$527K | ﹤0.01% | 1540 |
|
|
2013
Q3 | $11.4M | Sell |
556,823
-90,245
| -14% | -$1.86M | ﹤0.01% | 1681 |
|
|
2013
Q2 | $12.9M | Buy |
+647,068
| New | +$11.5M | ﹤0.01% | 1518 |
|
JP Morgan Chase's IPXL Position: Q2 2018 in Review
JP Morgan Chase sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 459,229 shares — an estimated $8.93M sold.
JP Morgan Chase first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $15.5M in Q2 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- JP Morgan Chase reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- JP Morgan Chase sold 459,229 Impax Laboratories, Inc. shares in Q2 2018, an estimated $8.93M.
- JP Morgan Chase first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- JP Morgan Chase's Impax Laboratories, Inc. position peaked at $15.5M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on JP Morgan Chase's 13F filing for Q2 2018, filed 14 Aug 2018.